Springer Nature [academic journals on nature.com], British Journal of Cancer, 4(125), p. 467-469, 2021
DOI: 10.1038/s41416-021-01285-1
Full text: Unavailable
SummaryEmerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.